Quest Diagnostics CFO reports 68-share buy; holds 25,741 shares
Quest Diagnostics (DGX) disclosed an insider transaction by its Executive Vice President & CFO.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Quest Diagnostics (DGX) disclosed an insider transaction by its Executive Vice President & CFO. On 10/21/2025, the officer acquired 68 shares of common stock at a price of $189.081 per share, reported as an acquisition through a dividend reinvestment plan. Following this transaction, the officer directly beneficially owns 25,741 shares. The filing also notes that dividend reinvestment plan shares are eligible for deferred reporting on Form 5 under Rule 16a-6, but the officer elected to report early on this Form 4.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 68 | $189.081 | $13K |
Footnotes (2)
- F1. Represents an award of restricted share units.
- F2. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did DGX report?
Why was this DGX transaction reported on Form 4?
What is the reporting person’s role at DGX?
AI-generated analysis. How Rhea-AI works. Not financial advice.